

Unbiased Proteomics to Reduce Risk in Drug Development

Do you understand who your therapy works for—and who it doesn't?

Early proteomic profiling reveals signatures associated with response and resistance


Case Study

Scripps Research Institute

Hodgkin Lymphoma patients treated with JAK + PD-1 combination therapy


Key Findings

- Identified early protein changes associated with therapeutic response
- Revealed modulation of **immune signaling pathways (e.g., JAK–STAT)**
- Distinguished **responders (R) vs non-responders (NR)** at early timepoints



Why It Matters for Development

- Reveals biological differences underlying response and resistance
- Provides insight into **pathways associated with therapeutic response**
- Supports hypothesis generation for **combination strategies and biomarker development**



Unbiased proteomic profiling distinguishes responders from non-responders

Why This Required Unbiased Proteomics

- Captured system-wide pathway changes beyond **single biomarker measurements**
- Enabled unbiased discovery of protein signatures associated with response heterogeneity
- Revealed coordinated immune signaling not detectable with **predefined panels**